102877-36-1

Usage

Appearance

Pale yellow to off-white solid

Usage

Primary intermediate in the manufacture of pharmaceuticals and other organic compounds

Applications

Building block for the synthesis of various medications (e.g. antihistamines and local anesthetics), production of fragrance and flavoring compounds, synthesis of specialty chemicals, potential use as a solvent and chemical reagent in laboratory settings.

Upstream product

• 79-21-0 peracetic acid 
• 1745-18-2 1-allyl-4-chlorobenzene 
• 80540-56-3 methyl 3-(4-chlorophenyl)-2-hydroxyacrylate 
• 104-88-1 4-chlorobenzaldehyde 
• 127273-12-5 3-(4-chlorophenyl)-2-hydroxyacrylic acid 
• 93634-55-0 2-methyl-4-(4-chlorobenzylidene)-4H-oxazol-5-one 

Downstream Products

• 68685-70-1 1-[4-(4-chloro-benzyl)-2-(2,4-dichloro-phenyl)-[1,3]dioxolan-2-ylmethyl]-1H-imidazole 
• 79146-75-1 2-Bromomethyl-4-(4-chloro-benzyl)-2-(2,4-dichloro-phenyl)-[1,3]dioxolane 

Relevant academic research and scientific papers

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Chemocontrolled reduction of aromatic α-ketoesters by NaBH4: Selective synthesis of α-hydroxy esters or 1,2-diols

α-Hydroxyesters 5a-g or diols 6a-g have been obtained in high yields by reduction of aromatic α-ketoesters 4 once or twice respectively by using NaBH4 as the reducer under suitable conditions. The use of a solvent that does not interact with the reagent allowed the double reduction to occur with only a slight excess of borohydride in very mild conditions.